Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2022 13:00 ET | Source: DelveInsight Business Research LLP

Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

New York, USA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Atopic...
November 15, 2022 16:01 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology

Peer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 ...
November 15, 2022 11:10 ET | Source: Arcutis Biotherapeutics, Inc.

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
November 15, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
November 14, 2022 17:27 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights

- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first...
November 08, 2022 06:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
September 07, 2022 17:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisLead indication, atopic dermatitis, is a rapidly...
September 07, 2022 01:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
August 23, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roﬂumilast Cream in Atopic Dermatitis

A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trialTopline data from both INTEGUMENT-1 and -2 trials expected by end of 2022Atopic dermatitis aﬀects...
August 04, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic...